Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

DSGNDesign Therapeutics, Inc.

Nasdaq · CIK 0001807120
Filer categoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts199

Identity from submissions API

NameDesign Therapeutics, Inc.
CIK0001807120
TickersDSGN
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SIC2834 Pharmaceutical Preparations
EIN823929248
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone858-293-4900
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • None listed.
Business address
6005 HIDDEN VALLEY ROAD
SUITE 110
CARLSBAD
CA
92011
CA
Mailing address
6005 HIDDEN VALLEY ROAD
SUITE 110
CARLSBAD
CA
92011
CA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

270 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-16 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000938206-26-000062 005-92462 261556599 34 7651
2026-11-12 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-26-003535 333-299827 261548839 33 1766
2026-11-04 S-3 S-3 0001193125-26-447545 333-299827 261523512 33 556714 1 1
2026-11-04 424B5 424B5 0001193125-26-447373 333-287043 261522788 33 81477
2026-11-04 10-Q 10-Q 0001193125-26-447258 001-40288 261522326 34 8948006 1 1
2026-11-04 8-K 8-K 2.02,9.01 0001193125-26-447235 001-40288 261522221 34 493397 1 1
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000919574-26-005487 005-92462 261281401 34 12272
2026-08-14 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000919574-26-005202 005-92462 261276426 34 15153
2026-08-03 10-Q 10-Q 0001193125-26-329579 001-40288 261230524 34 8512686 1 1
2026-08-03 8-K 8-K 2.02,9.01 0001193125-26-329570 001-40288 261230518 34 489252 1 1
2026-06-11 4 4 0001193125-26-267732 5452
2026-06-11 4 xslF345X06/form4-06112026_040611.xml 0001478916-26-000009 5667
2026-06-11 4 xslF345X06/form4-06112026_040609.xml 0001579826-26-000002 5702
2026-06-11 4 xslF345X06/form4-06112026_040607.xml 0001754129-26-000006 5712
2026-06-11 4 xslF345X06/form4-06112026_040613.xml 0001559570-26-000008 5685
2026-06-11 4 xslF345X06/form4-06112026_040606.xml 0001751873-26-000002 5785
2026-06-11 8-K 8-K 5.07 0001193125-26-267485 001-40288 261083005 34 169959 1 1
2026-06-09 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000919574-26-003921 005-92462 261076969 34 17673
2026-05-18 8-K 8-K 8.01 0001193125-26-227875 001-40288 26990769 34 154384 1 1
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000919574-26-003492 005-92462 26988270 34 12314
2026-04-28 10-Q 10-Q 0001193125-26-187063 001-40288 26907927 34 7689991 1 1
2026-04-28 8-K 8-K 2.02,7.01 0001193125-26-187012 001-40288 26907782 34 75951507 1 1
2026-04-23 DEFA14A DEFA14A 0001193125-26-173689 001-40288 26888687 34 4137314
2026-04-23 DEF 14A DEF 14A 0001193125-26-173678 001-40288 26888640 34 9068371 1 1
2026-04-23 ARS ARS 0001193125-26-173640 001-40288 26888493 34 4207244
2026-04-01 4 xslF345X06/form4-04012026_080415.xml 0001559570-26-000006 7812
2026-04-01 3 xslF345X06/form3-04012026_080440.xml 0001559570-26-000004 8152
2026-04-01 8-K 8-K 5.02 0001193125-26-137861 001-40288 26828067 34 156142 1 1
2026-03-11 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0001072613-26-000257 005-92462 26745427 34 125234
2026-03-09 S-8 S-8 0001193125-26-098540 333-294144 26735176 33 344323 1 1
2026-03-09 10-K 10-K 0001193125-26-098491 001-40288 26734991 34 26142252 1 1
2026-03-09 8-K 8-K 2.02,9.01 0001193125-26-098474 001-40288 26734915 34 489400 1 1
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-26-001131 005-92462 26642051 34 12313
2026-01-30 8-K 8-K 5.02 0001193125-26-031772 001-40288 26583353 34 140088 1 1
2026-01-05 4 xslF345X05/form4-01052026_090112.xml 0001674703-26-000002 5702
2026-01-05 4 xslF345X05/form4-01052026_090157.xml 0001848377-26-000002 5702
2026-01-05 4 xslF345X05/form4-01052026_090130.xml 0001883722-26-000002 5703
2026-01-05 4 xslF345X05/form4-01052026_090117.xml 0001754129-26-000002 5438
2026-01-05 4 xslF345X05/form4-01052026_090147.xml 0001580787-26-000002 5676
2025-12-11 4 xslF345X05/form4-12112025_041203.xml 0001580787-25-000006 8184
2025-11-18 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0000935836-25-000710 005-92462 251496145 34 28949
2025-11-18 144 xsl144X01/primary_doc.xml 0001178937-25-000065 001-40288 251495134 33 5690
2025-11-14 144 xsl144X01/primary_doc.xml 0001178937-25-000060 001-40288 251486644 33 5090
2025-11-12 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0000935836-25-000657 005-92462 251474169 34 27785
2025-11-07 144 xsl144X01/primary_doc.xml 0001178937-25-000059 001-40288 251463694 33 5093
2025-11-05 10-Q 10-Q 0001193125-25-266970 001-40288 251454218 34 8725592 1 1
2025-11-05 8-K 8-K 2.02,9.01 0001193125-25-266933 001-40288 251454054 34 488835 1 1
2025-09-10 4 xslF345X05/form4-09102025_090913.xml 0001415889-25-024109 7710
2025-09-10 3 xslF345X02/form3-09102025_090926.xml 0001415889-25-024108 8074
2025-09-10 8-K 8-K 5.02 0001807120-25-000004 001-40288 251305887 34 157872 1 1
2025-08-28 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-003881 005-92462 251273350 34 18081
2025-08-14 4 xslF345X05/form4-08142025_040805.xml 0001415889-25-021842 7425
2025-08-13 144 xsl144X01/primary_doc.xml 0001178937-25-000028 001-40288 251213710 33 4516
2025-08-13 144 xsl144X01/primary_doc.xml 0001178937-25-000027 001-40288 251213708 33 4534
2025-08-07 10-Q 10-Q 0000950170-25-105062 001-40288 251194346 34 8818845 1 1
2025-08-07 8-K 8-K 2.02,7.01 0000950170-25-105008 001-40288 251194003 34 24225907 1 1
2025-06-12 4 4 0000950170-25-085506 5289
2025-06-12 4 xslF345X05/form4-06122025_040608.xml 0001415889-25-016957 5550
2025-06-12 4 xslF345X05/form4-06122025_040614.xml 0001415889-25-016959 5561
2025-06-12 4 xslF345X05/form4-06122025_040606.xml 0001415889-25-016956 5648
2025-06-12 4 xslF345X05/form4-06122025_040611.xml 0001415889-25-016958 5530
2025-06-12 4 xslF345X05/form4-06122025_040604.xml 0001415889-25-016955 5565
2025-06-12 8-K 8-K 5.07 0000950170-25-085380 001-40288 251042773 34 175066 1 1
2025-05-23 4 xslF345X05/form4-05232025_080531.xml 0001415889-25-014477 5543
2025-05-23 3 xslF345X02/form3-05232025_080546.xml 0001415889-25-014473 8041
2025-05-16 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-001643 333-287043 25961391 33 1765
2025-05-14 CORRESP filename1.htm 0001193125-25-119753 7408
2025-05-13 UPLOAD filename1.pdf 0000000000-25-005100 333-287043 40132
2025-05-07 S-3 S-3 0001193125-25-114986 333-287043 25922442 33 1279188
2025-05-07 10-Q 10-Q 0000950170-25-065643 001-40288 25921350 34 8018324 1 1
2025-05-07 8-K 8-K 2.02,9.01 0000950170-25-065613 001-40288 25921190 34 466094 1 1
2025-04-30 DEFR14A DEFR14A 0000950170-25-061037 001-40288 25895027 34 5189317 1 1
2025-04-24 ARS ARS 0000950170-25-058051 001-40288 25867482 34 22582950
2025-04-24 DEFA14A DEFA14A 0000950170-25-058022 001-40288 25867370 34 1102937
2025-04-24 DEF 14A DEF 14A 0000950170-25-058008 001-40288 25867279 34 3261176
2025-03-10 S-8 S-8 0000950170-25-035913 333-285660 25722149 33 359624 1 1
2025-03-10 10-K 10-K 0000950170-25-035910 001-40288 25722137 34 29095904 1 1
2025-03-10 8-K 8-K 2.02,9.01 0000950170-25-035909 001-40288 25722132 34 478157 1 1
2025-02-07 3 xslF345X02/form3-02072025_090223.xml 0001415889-25-003349 8989
2025-02-07 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001415889-25-003348 005-92462 25601948 34 9435
2025-02-07 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001415889-25-003347 005-92462 25601927 34 9443
2025-01-13 8-K 8-K 7.01,9.01 0000950170-25-004612 001-40288 25525067 34 7463762 1 1
2025-01-06 4 xslF345X05/form4-01062025_070132.xml 0001415889-25-000880 5475
2025-01-06 4 xslF345X05/form4-01062025_070130.xml 0001415889-25-000879 5710
2025-01-06 4 xslF345X05/form4-01062025_070127.xml 0001415889-25-000878 5683
2025-01-06 4 xslF345X05/form4-01062025_070125.xml 0001415889-25-000877 5709
2024-12-19 4 xslF345X05/form4-12192024_061201.xml 0001415889-24-029913 4634
2024-11-07 10-Q 10-Q 0000950170-24-123349 001-40288 241435865 34 7429292 1 1
2024-11-07 8-K 8-K 2.02,9.01 0000950170-24-123289 001-40288 241435556 34 448770 1 1
2024-08-13 SC 13D/A dsgn13d.htm 0000935836-24-000514 005-92462 241203600 34 74633
2024-08-12 4 xslF345X05/form4-08122024_080818.xml 0001415889-24-021086 7508
2024-08-09 144 xsl144X01/primary_doc.xml 0001178937-24-000042 001-40288 241193112 33 4486
2024-08-05 10-Q 10-Q 0000950170-24-090337 001-40288 241173173 34 7262929 1 1
2024-08-05 8-K 8-K 2.02,9.01 0000950170-24-090332 001-40288 241173144 34 446706 1 1
2024-06-17 4 4 0000950170-24-074363 5296
2024-06-17 4 xslF345X05/form4-06172024_050620.xml 0001415889-24-017241 5568
2024-06-17 4 xslF345X05/form4-06172024_050616.xml 0001415889-24-017239 5572
2024-06-17 4 xslF345X05/form4-06172024_050618.xml 0001415889-24-017240 5537
2024-06-17 4 xslF345X05/form4-06172024_050614.xml 0001415889-24-017238 5655
2024-06-17 4 xslF345X05/form4-06172024_050611.xml 0001415889-24-017237 5557
2024-06-17 8-K 8-K 5.07 0000950170-24-074243 001-40288 241048345 34 170150 1 1
2024-05-08 10-Q 10-Q 0000950170-24-055788 001-40288 24926738 34 6741322 1 1
2024-05-08 8-K 8-K 2.02,9.01 0000950170-24-055645 001-40288 24926058 34 425187 1 1
2024-04-25 ARS ARS 0000950170-24-048411 001-40288 24876999 34 15049710
2024-04-25 DEFA14A DEFA14A 0000950170-24-048399 001-40288 24876932 34 290209
2024-04-25 DEF 14A DEF 14A 0000950170-24-048385 001-40288 24876874 34 1464849
2024-03-25 4 xslF345X05/form4-03252024_110321.xml 0001415889-24-009063 7342
2024-03-25 4 xslF345X05/form4-03252024_110307.xml 0001415889-24-009062 4714
2024-03-20 3 xslF345X02/form3-03202024_110345.xml 0001415889-24-008788 14362
2024-03-19 S-8 S-8 0000950170-24-033525 333-278064 24763687 33 154022
2024-03-19 10-K 10-K 0000950170-24-033492 001-40288 24763484 34 34937688 1 1
2024-03-19 8-K 8-K 2.02,9.01 0000950170-24-033475 001-40288 24763345 34 321291 1 1
2024-02-14 SC 13G/A SC 13G/A 0001104659-24-023960 005-92462 24640017 34 137868
2024-02-14 SC 13G/A AMENDMENT NO. 3 0000929638-24-000641 005-92462 24636486 34 148104
2024-01-23 SC 13G/A Design_Th_Inc.txt 0000093751-24-000097 005-92462 24550880 34 8421
2024-01-05 4 FORM 4 SUBMISSION 0001209191-24-001042 5760
2024-01-05 4 FORM 4 SUBMISSION 0001209191-24-001039 5759
2023-12-05 4 FORM 4 SUBMISSION 0001209191-23-057552 5441
2023-12-05 4 FORM 4 SUBMISSION 0001209191-23-057548 5441
2023-11-14 SC 13G/A SC 13G/A 0001104659-23-118212 005-92462 231407673 34 84811
2023-11-13 10-Q 10-Q 0000950170-23-062958 001-40288 231398898 34 8870329 1 1
2023-11-13 8-K 8-K 2.02,9.01 0000950170-23-062937 001-40288 231398751 34 366977 1 1
2023-10-02 4 FORM 4 SUBMISSION 0001209191-23-051175 4991
2023-09-07 SC 13G/A us25056l1035_090623.txt 0001306550-23-009874 005-92462 231241216 34 12471
2023-09-06 4/A FORM 4/A SUBMISSION 0001209191-23-048441 10365
2023-09-05 4 FORM 4 SUBMISSION 0001209191-23-048222 10818
2023-08-30 4 FORM 4 SUBMISSION 0001209191-23-047774 5064
2023-08-30 4 FORM 4 SUBMISSION 0001209191-23-047773 10086
2023-08-25 8-K 8-K 5.02 0001193125-23-221586 001-40288 231209153 34 153413 1 1
2023-08-14 10-Q 10-Q 0000950170-23-042411 001-40288 231170208 34 8871878 1 1
2023-08-14 8-K 8-K 2.02,9.01 0000950170-23-042392 001-40288 231169972 34 404625 1 1
2023-06-02 4 FORM 4 SUBMISSION 0001209191-23-033847 5444
2023-06-02 4 FORM 4 SUBMISSION 0001209191-23-033787 5481
2023-06-02 4 FORM 4 SUBMISSION 0001209191-23-033784 5461
2023-06-02 4 FORM 4 SUBMISSION 0001209191-23-033785 5469
2023-06-02 4 FORM 4 SUBMISSION 0001209191-23-033782 5492
2023-06-02 4 FORM 4 SUBMISSION 0001209191-23-033781 5579
2023-06-02 4 FORM 4 SUBMISSION 0001209191-23-033778 5496
2023-06-01 8-K 8-K 5.07 0001193125-23-159009 001-40288 23985347 34 156885 1 1
2023-05-09 10-Q 10-Q 0000950170-23-019714 001-40288 23902359 34 7674056 1 1
2023-05-09 8-K 8-K 2.02,9.01 0000950170-23-019682 001-40288 23902160 34 372838 1 1
2023-04-13 ARS ARS 0000950170-23-012726 001-40288 23818841 34 3100498
2023-04-13 DEFA14A DEFA14A 0000950170-23-012725 001-40288 23818808 34 2772440
2023-04-13 DEF 14A DEF 14A 0000950170-23-012723 001-40288 23818795 34 1285748
2023-04-03 SC 13G DESIGN THERAPEUTICS, INC. 0001104659-23-040937 005-92462 23793590 34 138319
2023-03-14 S-8 S-8 0000950170-23-007877 333-270527 23731383 33 222895
2023-03-14 10-K 10-K 0000950170-23-007869 001-40288 23731046 34 13165769 1 1
2023-03-14 8-K 8-K 2.02,9.01 0000950170-23-007864 001-40288 23730782 34 408270 1 1
2023-02-14 SC 13G/A schedule13g.htm 0000929638-23-000569 005-92462 23627789 34 148331
2023-02-14 SC 13G/A SC 13G/A 0001104659-23-020770 005-92462 23622717 34 137840
2023-02-08 SC 13G Design_Therapeutics_Inc.txt 0000093751-23-000361 005-92462 23598205 34 8347
2023-02-03 4 FORM 4 SUBMISSION 0001209191-23-006927 5644
2023-02-03 4 FORM 4 SUBMISSION 0001209191-23-006921 5646
2023-02-03 4 FORM 4 SUBMISSION 0001209191-23-006917 5612
2023-02-03 4 FORM 4 SUBMISSION 0001209191-23-006910 5606
2023-02-03 SC 13G us25056l1035_020323.txt 0001306550-23-007105 005-92462 23584717 34 13200
2022-12-22 SC 13D/A SC 13D/A 0001193125-22-311061 005-92462 221482265 34 196798
2022-12-22 SC 13G SC 13G 0001104659-22-129507 005-92462 221481960 34 132345
2022-12-21 4 FORM 4 SUBMISSION 0001209191-22-062349 6850
2022-12-20 4 FORM 4 SUBMISSION 0001209191-22-062227 24561
2022-12-20 4 FORM 4 SUBMISSION 0001209191-22-062226 28062
2022-12-12 4 FORM 4 SUBMISSION 0001209191-22-060738 4961
2022-11-03 10-Q 10-Q 0000950170-22-021885 001-40288 221358237 34 8873033 1 1
2022-11-03 8-K 8-K 2.02,9.01 0000950170-22-021862 001-40288 221358051 34 415955 1 1
2022-10-13 SC 13G SC 13G 0001104659-22-108513 005-92462 221309341 34 83414
2022-08-08 10-Q 10-Q 0000950170-22-015533 001-40288 221144511 34 8391528 1 1
2022-08-08 8-K 8-K 2.02,9.01 0000950170-22-015520 001-40288 221144407 34 399761 1 1
2022-06-16 4 FORM 4 SUBMISSION 0001209191-22-037525 5440
2022-06-16 4 FORM 4 SUBMISSION 0001209191-22-037524 5467
2022-06-16 4 FORM 4 SUBMISSION 0001209191-22-037517 5432
2022-06-16 4 FORM 4 SUBMISSION 0001209191-22-037514 5463
2022-06-16 4 FORM 4 SUBMISSION 0001209191-22-037511 5432
2022-06-16 4 FORM 4 SUBMISSION 0001209191-22-037509 5452
2022-06-16 4 FORM 4 SUBMISSION 0001209191-22-037503 5550
2022-06-16 8-K 8-K 5.07 0000950170-22-011751 001-40288 221020891 34 196913 1 1
2022-05-09 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2022-05-09 17:00:00 9999999995-22-001375 333-264521 22907154 33 1723
2022-05-09 10-Q 10-Q 0000950170-22-008500 001-40288 22905117 34 7395082 1 1
2022-05-09 8-K 8-K 2.02,9.01 0000950170-22-008486 001-40288 22904986 34 354129 1 1
2022-05-05 CORRESP filename1.htm 0001193125-22-142131 7950
2022-05-02 CORRESP filename1.htm 0001193125-22-136205 7421
2022-04-29 UPLOAD filename1.pdf 0000000000-22-004681 40219
2022-04-27 S-3 S-3 0001193125-22-123965 333-264521 22861073 33 1320205
2022-04-27 DEFA14A DEFA14A 0001193125-22-123696 001-40288 22860047 34 37953
2022-04-27 DEF 14A DEF 14A 0001193125-22-123683 001-40288 22859993 34 521824
2022-03-31 SC 13D dsgn13d.htm 0000935836-22-000298 005-92462 22792903 34 56575
2022-03-22 4 FORM 4 SUBMISSION 0001209191-22-020638 7318
2022-03-22 4 FORM 4 SUBMISSION 0001209191-22-020637 12873
2022-03-22 8-K 8-K 1.01,9.01 0000950170-22-004311 001-40288 22760080 34 302521 1 1
2022-03-18 4 FORM 4 SUBMISSION 0001209191-22-020082 4676
2022-03-10 S-8 S-8 0001193125-22-072001 333-263427 22729501 33 60936
2022-03-10 10-K 10-K 0000950170-22-003369 001-40288 22729257 34 12728631 1 1
2022-03-10 8-K 8-K 2.02,9.01 0000950170-22-003356 001-40288 22729093 34 398647 1 1
2022-02-14 SC 13G/A schedule13g.htm 0000929638-22-000480 005-92462 22630197 34 153936
2022-02-09 SC 13G SC 13G 0001193125-22-032746 005-92462 22607698 34 37529
2022-02-09 SC 13G SC 13G 0001193125-22-032735 005-92462 22607623 34 66547
2022-02-09 SC 13G SC 13G 0001193125-22-032725 005-92462 22607568 34 62125
2022-02-02 4 FORM 4 SUBMISSION 0001209191-22-006581 5647
2022-02-02 4 FORM 4 SUBMISSION 0001209191-22-006579 5613
2022-02-02 4 FORM 4 SUBMISSION 0001209191-22-006577 5607
2022-02-02 4 FORM 4 SUBMISSION 0001209191-22-006576 5645
2021-11-09 10-Q 10-Q 0000950170-21-003753 001-40288 211392422 34 8562379 1 1
2021-11-09 8-K 8-K 2.02,9.01 0000950170-21-003747 001-40288 211392255 34 393111 1 1
2021-10-04 4 FORM 4 SUBMISSION 0001209191-21-059038 5539
2021-09-20 3 FORM 3 SUBMISSION 0001209191-21-056960 6135
2021-09-02 4 FORM 4 SUBMISSION 0001209191-21-054492 7731
2021-08-20 8-K 8-K 5.02 0001193125-21-252071 001-40288 211191723 34 152509 1 1
2021-08-17 3 FORM 3 SUBMISSION 0001209191-21-052064 9144
2021-08-09 10-Q 10-Q 0001564590-21-042734 001-40288 211157491 34 7810342 1 1
2021-08-09 8-K 8-K 2.02,9.01 0001564590-21-042617 001-40288 211156436 34 440217 1 1
2021-08-06 8-K 8-K 5.02 0001193125-21-239304 001-40288 211153377 34 18492
2021-06-16 4 FORM 4 SUBMISSION 0001209191-21-040998 5433
2021-06-16 3 FORM 3 SUBMISSION 0001209191-21-040994 8322
2021-06-16 4 FORM 4 SUBMISSION 0001209191-21-040988 5431
2021-06-16 3 FORM 3 SUBMISSION 0001209191-21-040983 6054
2021-06-07 8-K 8-K 5.02 0001564590-21-031964 001-40288 21999825 34 30532
2021-05-10 10-Q 10-Q 0001564590-21-026062 001-40288 21907421 34 6172938 1
2021-05-10 8-K 8-K 2.02,9.01 0001564590-21-026050 001-40288 21907250 34 233541
2021-04-09 SC 13G schedule13g.htm 0000929638-21-000600 005-92462 21817897 34 168122
2021-04-09 SC 13D SC 13D 0001193125-21-111505 005-92462 21817723 34 144665
2021-04-01 4 FORM 4 SUBMISSION 0001209191-21-024248 4825
2021-04-01 4 FORM 4 SUBMISSION 0001209191-21-024242 11209
2021-04-01 4 FORM 4 SUBMISSION 0001209191-21-024238 17247
2021-04-01 4 FORM 4 SUBMISSION 0001209191-21-024234 13735
2021-04-01 4 FORM 4 SUBMISSION 0001209191-21-024233 13927
2021-04-01 4 FORM 4 SUBMISSION 0001209191-21-024231 4639
2021-04-01 4 FORM 4 SUBMISSION 0001209191-21-024229 9643
2021-04-01 4 FORM 4 SUBMISSION 0001209191-21-024226 4701
2021-04-01 4 FORM 4 SUBMISSION 0001209191-21-024224 14347
2021-04-01 4 FORM 4 0001567619-21-007374 20460
2021-03-30 3/A FORM 3/A SUBMISSION 0001209191-21-023612 10219
2021-03-30 8-K 8-K 5.03,8.01,9.01 0001193125-21-100253 001-40288 21786556 34 183412
2021-03-29 4 FORM 4 SUBMISSION 0001209191-21-023472 5263
2021-03-29 4 FORM 4 SUBMISSION 0001209191-21-023466 5286
2021-03-29 4 FORM 4 SUBMISSION 0001209191-21-023465 5255
2021-03-29 4 FORM 4 SUBMISSION 0001209191-21-023463 5290
2021-03-29 4 FORM 4 SUBMISSION 0001209191-21-023462 5255
2021-03-26 S-8 S-8 0001193125-21-096749 333-254794 21778478 33 86376
2021-03-26 424B4 424B4 0001193125-21-096741 333-253954 21778426 33 3735653
2021-03-25 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2021-03-25 16:00:00 9999999995-21-001140 333-253954 21774464 33 1687
2021-03-25 3 FORM 3 SUBMISSION 0001209191-21-023128 6556
2021-03-25 3 FORM 3 SUBMISSION 0001209191-21-023127 11011
2021-03-25 3 FORM 3 SUBMISSION 0001209191-21-023126 9267
2021-03-25 3 FORM 3 SUBMISSION 0001209191-21-023125 7304
2021-03-25 3 FORM 3 SUBMISSION 0001209191-21-023124 6981
2021-03-25 3 FORM 3 SUBMISSION 0001209191-21-023122 7714
2021-03-25 3 FORM 3 SUBMISSION 0001209191-21-023121 8142
2021-03-25 3 FORM 3 SUBMISSION 0001209191-21-023120 6606
2021-03-25 3 FORM 3 SUBMISSION 0001209191-21-023119 6985
2021-03-25 3 FORM 3 SUBMISSION 0001209191-21-023118 6642
2021-03-25 3 FORM 3 SUBMISSION 0001209191-21-023117 9477
2021-03-25 3 FORM 3 SUBMISSION 0001209191-21-023114 6680
2021-03-25 3 FORM 3 SUBMISSION 0001209191-21-023112 3507
2021-03-25 3 FORM 3 0001567619-21-006965 14743
2021-03-24 CERT 8A_Cert_DSGN.pdf 0001354457-21-000410 001-40288 21769155 34 197535
2021-03-24 SEC STAFF LETTER filename1.pdf 9999999997-21-001403 275500
2021-03-23 8-A12B 8-A12B 0001193125-21-091210 001-40288 21765006 34 13589
2021-03-23 CORRESP filename1.htm 0001193125-21-091190 11581
2021-03-23 CORRESP filename1.htm 0001193125-21-091180 9106
2021-03-22 CORRESP filename1.htm 0001193125-21-088362 17974
2021-03-22 S-1/A S-1/A 0001193125-21-088348 333-253954 21759802 33 4908085
2021-03-18 UPLOAD filename1.pdf 0000000000-21-003281 44406
2021-03-16 CORRESP filename1.htm 0001193125-21-082015 82969
2021-03-05 CORRESP filename1.htm 0001193125-21-071686 35062
2021-03-05 S-1 S-1 0001193125-21-071667 333-253954 21719604 33 5678319
2021-02-23 SEC STAFF LETTER filename1.pdf 9999999997-21-000959 276639
2021-02-23 UPLOAD filename1.pdf 0000000000-21-002174 53396
2021-02-12 D xslFormDX01/primary_doc.xml 06b 0001807120-21-000002 021-389403 21628276 33 11859
2021-01-26 DRS filename1.htm 0000950123-21-000626 377-04103 21554999 33 5020374
2020-06-03 D/A xslFormDX01/primary_doc.xml 06b 0001807120-20-000002 021-363353 20938289 33 10210
2020-03-20 D xslFormDX01/primary_doc.xml 06b 0001807120-20-000001 021-363353 20731212 33 10115

Latest XBRL company facts

One latest value per concept from companyfacts (199 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 64.04M 2026-10-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
dei EntityPublicFloat Entity Public Float USD 114.34M 2025-06-30 2025 FY 10-K 2026-03-09 0001193125-26-098491
ffd NetFeeAmt NetFeeAmt USD 26,100 2026-11-03 S-3 2026-11-04 0001193125-26-447545
ffd TtlFeeAmt TtlFeeAmt USD 26,100 2026-11-03 S-3 2026-11-04 0001193125-26-447545
ffd TtlOfferingAmt TtlOfferingAmt USD 300.00M 2026-11-03 S-3 2026-11-04 0001193125-26-447545
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-11-03 S-3 2026-11-04 0001193125-26-447545
ffd TtlPrevslyPdAmt TtlPrevslyPdAmt USD 0 2026-11-03 S-3 2026-11-04 0001193125-26-447545
us-gaap AccountsPayableAndOtherAccruedLiabilitiesCurrent Accounts Payable and Other Accrued Liabilities, Current USD 10.68M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 2.08M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap AccountsPayableRelatedPartiesCurrent Accounts Payable, Related Parties, Current USD 8,000 2022-06-30 2022 Q2 10-Q 2022-08-08 0000950170-22-015533
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 144,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 10.68M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 2.71M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -1.68M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap AdditionalPaidInCapitalCommonStock Additional Paid in Capital, Common Stock USD 558.97M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 11.84M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 11.84M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 17.85M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap Assets Assets USD 216.81M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap AssetsCurrent Assets, Current USD 213.96M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 4,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 1.69M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 195.04M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap AvailableForSaleSecuritiesDebtSecuritiesCurrent Debt Securities, Available-for-sale, Current USD 193.36M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 0 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-04-28 0001193125-26-187063
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 15.25M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-term Investments USD 208.60M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 15.25M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD -1.60M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 200.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 63.79M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 63.79M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap CommonStockValue Common Stock, Value, Issued USD 6,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -60.17M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap ConversionOfStockAmountConverted1 Conversion of Stock, Amount Converted USD 271,000 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003369
us-gaap ConvertibleDebt Convertible Debt USD 200,000 2019-02-28 2021 FY 10-K 2022-03-10 0000950170-22-003369
us-gaap CurrentIncomeTaxExpenseBenefit Current Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap DebtConversionOriginalDebtAmount1 Debt Conversion, Original Debt, Amount USD 500,000 2020-02-01 2020-02-29 2021 FY 10-K 2022-03-10 0000950170-22-003369
us-gaap DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage pure 0.08 2019-02-28 2021 FY 10-K 2022-03-10 0000950170-22-003369
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer USD 490,000 2024-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss USD 304,000 2023-12-31 2024 FY 10-K 2025-03-10 0000950170-25-035910
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months USD 175.87M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss USD 1.69M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions Security 38 2021-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003369
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPosition Debt Securities, Available-for-sale, Unrealized Loss Position USD 175.87M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss USD 1.69M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions Security 63 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap DeferredCosts Deferred Costs, Noncurrent USD 212,000 2020-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003369
us-gaap DeferredIncomeTaxExpenseBenefit Deferred Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 67.87M 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 546,000 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 31.41M 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 1.03M 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsResearch Deferred Tax Assets, Tax Credit Carryforwards, Research USD 11.68M 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 3.81M 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 67.33M 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap DeferredTaxLiabilities Deferred Tax Liabilities, Net USD 546,000 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap DeferredTaxLiabilitiesOther Deferred Tax Liabilities, Other USD 241,000 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount USD 500,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap DepositsAssetsCurrent Deposits Assets, Current USD 47,000 2020-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003369
us-gaap Depreciation Depreciation USD 444,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -0.93 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -0.24 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-09 0000950170-22-008500
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -0.93 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.19 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent pure -0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.02 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure 0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount USD 1.72M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent pure -0.025 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0.003 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap EffectiveIncomeTaxRateReconciliationTaxContingencies Effective Income Tax Rate Reconciliation, Tax Contingency, Percent pure -0.007 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure -0.029 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 3.93M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount USD 20.70M 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 16.42M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap ImpairmentOfLongLivedAssetsHeldForUse Impairment of Long-Lived Assets Held-for-use USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap IncomeTaxesPaidNet Income Taxes Paid, Net USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap IncomeTaxExaminationPenaltiesAndInterestAccrued Income Tax Examination, Penalties and Interest Accrued USD 0 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap IncomeTaxExaminationPenaltiesAndInterestExpense Income Tax Examination, Penalties and Interest Expense USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 13.27M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -14.66M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap IncomeTaxReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount USD 25,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 1.38M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD -38,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD -181,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap IncomeTaxReconciliationTaxContingencies Effective Income Tax Rate Reconciliation, Tax Contingency, Amount USD 474,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 2.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities USD 1.07M 2021-01-01 2021-06-30 2021 Q2 10-Q 2021-08-09 0001564590-21-042734
us-gaap IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities Increase (Decrease) in Accounts Payable and Other Operating Liabilities USD -115,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap IncreaseDecreaseInDeferredRevenue Increase (Decrease) in Deferred Revenue USD -201,000 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003369
us-gaap IncreaseDecreaseInOtherNoncurrentLiabilities Increase (Decrease) in Other Noncurrent Liabilities USD 144,000 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003369
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD 1.42M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap InterestExpenseRelatedParty Interest Expense, Related Party USD 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003369
us-gaap InterestPaidNet Interest Paid, Excluding Capitalized Interest, Operating Activities USD 24,000 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003369
us-gaap InterestReceivableCurrent Interest Receivable, Current USD 1.74M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap InvestmentIncomeInterest Investment Income, Interest USD 6.02M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap InvestmentsFairValueDisclosure Investments, Fair Value Disclosure USD 206.43M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 2.99M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Lessee, Operating Lease, Liability, to be Paid, after Year Five USD 561,000 2021-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003369
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 898,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 663,000 2022-12-31 2022 FY 10-K 2023-03-14 0000950170-23-007869
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 663,000 2023-12-31 2023 FY 10-K 2024-03-19 0000950170-24-033492
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 952,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 925,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 218,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 479,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap Liabilities Liabilities USD 14.61M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 216.81M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap LiabilitiesCurrent Liabilities, Current USD 12.75M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap MarketableSecuritiesCurrent Marketable Securities, Current USD 193.36M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 38.07M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD 7.66M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -47.33M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -58.09M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap NumberOfReportableSegments Number of Reportable Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap OperatingExpenses Operating Expenses USD 64.11M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -64.11M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap OperatingLeaseCost Operating Lease, Cost USD 700,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 2.51M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 655,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 1.86M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 2.27M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap OperatingLeaseRightOfUseAssetAmortizationExpense Operating Lease, Right-of-Use Asset, Amortization Expense USD 6,000 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-10 0000950170-25-035910
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.107 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 717,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap OtherAssets Other Assets USD 0 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap OtherAssetsCurrent Other Assets, Current USD 7,000 2021-12-31 2022 Q3 10-Q 2022-11-03 0000950170-22-021885
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax USD -2.08M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 145,000 2020-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003369
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD 9.75M 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-07 0000950170-24-123349
us-gaap OtherOperatingActivitiesCashFlowStatement Other Operating Activities, Cash Flow Statement USD 4,000 2022-01-01 2022-12-31 2023 FY 10-K 2024-03-19 0000950170-24-033492
us-gaap PaidInKindInterest Paid-in-Kind Interest USD 12,000 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003369
us-gaap PaymentsOfDebtIssuanceCosts Payments of Debt Issuance Costs USD 427,000 2022-01-01 2022-12-31 2023 FY 10-K 2024-03-19 0000950170-24-033492
us-gaap PaymentsToAcquireInvestments Payments to Acquire Investments USD 94.81M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 36,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 5.36M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap PrepaidExpenseCurrent Prepaid Expense, Current USD 3.61M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 254.27M 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-14 0000950170-23-007869
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 37.16M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap ProceedsFromIssuanceOfConvertiblePreferredStock Proceeds from Issuance of Convertible Preferred Stock USD 124.71M 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-14 0000950170-23-007869
us-gaap ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised USD 35,000 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-09 0000950170-21-003753
us-gaap ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities Proceeds from Sale and Maturity of Debt Securities, Available-for-sale USD 102.50M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap ProceedsFromSaleOfProductiveAssets Proceeds from Sale of Productive Assets USD 39,000 2022-01-01 2022-12-31 2023 FY 10-K 2024-03-19 0000950170-24-033492
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 445,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -58.09M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 3.28M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 573,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty Related Party Transaction, Expenses from Transactions with Related Party USD 259,000 2023-01-01 2023-03-31 2023 Q1 10-Q 2023-05-09 0000950170-23-019714
us-gaap RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party USD 135,000 2023-01-01 2023-03-31 2023 Q1 10-Q 2023-05-09 0000950170-23-019714
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 47.69M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -355.10M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Revenue from Contract with Customer, Excluding Assessed Tax USD 226,000 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003369
us-gaap Revenues Revenues USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 11.84M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price USD/shares 13.5 2022-12-31 2022 FY 10-K 2023-03-14 0000950170-23-007869
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 0.85 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.043 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 21.67B 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 6.67M 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 8.12 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 300,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period shares 167,584 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 4.40M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 4.29 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 53.72B 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 17.81M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 7.31 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value USD 52.86B 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number shares 13.63M 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price USD/shares 6.51 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 4.62 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price USD/shares 7.08 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 9.79 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 202.20M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 0.613 2021-03-01 2021-03-31 2022 FY 10-K 2023-03-14 0000950170-23-007869
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 184,916 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 170.07M 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-14 0000950170-23-007869
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 464,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 37.12M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 445,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap TemporaryEquityCarryingAmountAttributableToParent Temporary Equity, Carrying Amount, Attributable to Parent USD 45.36M 2020-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003369
us-gaap TemporaryEquityLiquidationPreference Temporary Equity, Liquidation Preference USD 0 2021-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003369
us-gaap TemporaryEquityParOrStatedValuePerShare Temporary Equity, Par or Stated Value Per Share USD/shares 0 2021-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003369
us-gaap TemporaryEquitySharesAuthorized Temporary Equity, Shares Authorized shares 0 2021-09-30 2021 Q3 10-Q 2021-11-09 0000950170-21-003753
us-gaap TemporaryEquitySharesIssued Temporary Equity, Shares Issued shares 0 2021-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003369
us-gaap TemporaryEquitySharesOutstanding Temporary Equity, Shares Outstanding shares 0 2021-12-31 2021 FY 10-K 2022-03-10 0000950170-22-003369
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 2.81M 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions USD 523,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-09 0001193125-26-098491
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions USD 87,000 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-19 0000950170-24-033492
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 62.33M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 55.51M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-09 0000950170-22-008500
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 62.33M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447258

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →